Despite showing no meaningful benefit on lung function, Arcturus’ mRNA therapy ARCT-032 reduced mucus volume in patients with ...

Arcturus Therapeutics Holdings Inc. faces a solid cash runway into 2028, pipeline setbacks, and risk/reward profile. Learn ...

Therapeutics and Global Markets" report has been added to ResearchAndMarkets.com's offering.The global market for mRNA therapeutics was valued at $7.71 billion in 2025 and is forecast to remain stable ...

A new preliminary study published in Nature suggests that COVID-19 vaccines might actually boost the immune system to make ...

The relatively new mRNA vaccines, which gained significant recognition during the coronavirus pandemic, are now also being ...

Arcturus Therapeutics shares plunged 56% after Phase 2 cystic fibrosis trial data showed no meaningful lung function ...

Arcturus Therapeutics (ARCT) stock falls as Citi downgrades the company following weak mid-stage trial data for its cystic ...

On October 22, 2025, Arcturus Therapeutics Holdings announced interim Phase 2 clinical results for ARCT-032, its investigational inhaled mRNA therapy for cystic fibrosis, sharing details on mucus ...

Groundbreaking research reveals mRNA COVID-19 vaccines may significantly boost cancer treatment. A study found patients ...

Arcturus stock drops on interim Phase 2 results for ARCT-032, showing promising mucus reduction in cystic fibrosis patients ...

Vishal Mukund Sonje, Vaccine Manufacturing Lead, CEPI, talks about the challenges that arise in the manufacturing of vaccines ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...